Form 4: Alkermes Executive Samuel Joseph Parisi Reports Stock Transactions
SEC Form 4 Filing
Alkermes' VP of Finance, Samuel Joseph Parisi, reports the acquisition and disposal of ordinary shares and restricted stock units.
Summary
- Samuel Joseph Parisi, VP of Finance (Interim PAO) at Alkermes plc, filed a Form 4 detailing changes in beneficial ownership.
- On February 22, 2025, Parisi acquired 3,114 ordinary shares through the vesting of restricted stock units and disposed of 983 shares to cover tax obligations at a price of $35.32.
- On February 23, 2025, Parisi acquired 2,284 ordinary shares through the vesting of restricted stock units and disposed of 672 shares to cover tax obligations at a price of $35.32.
- On February 25, 2025, Parisi sold 3,743 ordinary shares at a price of $35.26.
- Following these transactions, Parisi beneficially owns 7,717 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't convey any particularly positive or negative sentiment about the company's performance or future prospects.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. It doesn't necessarily indicate a change in the company's prospects but provides transparency into executive stock ownership.
Comparison to Industry Standards
- Executive stock transactions are a common occurrence in publicly traded companies, including those in the pharmaceutical sector like Alkermes.
- Similar filings are regularly made by executives at companies like Biogen, Vertex Pharmaceuticals, and Amgen.
- The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading, ensuring transactions are pre-planned and executed according to a set schedule.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
- Employees may be indirectly affected by the executive's actions, but the impact is not expected to be significant.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of adoption of Rule 10b5-1 trading plan. |
| 02/22/2025 | Acquisition of 3,114 shares via restricted stock units and disposal of 983 shares for tax obligations. |
| 02/23/2024 | Commencement date for vesting of restricted stock unit award in four equal annual installments. |
| 02/23/2025 | Acquisition of 2,284 shares via restricted stock units and disposal of 672 shares for tax obligations. |
| 02/25/2025 | Sale of 3,743 shares under Rule 10b5-1 trading plan. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.